Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. develops allosteric small molecule therapies for neurodegenerative and other difficult-to-treat diseases. The company’s lead candidate, GT-02287, is being developed for Parkinson’s disease with or without a GBA1 mutation and is designed as a brain-penetrant allosteric enzyme modulator of glucocerebrosidase, or GCase.
Recurring news for GANX includes financial results, corporate updates, clinical and biomarker data for GT-02287, FDA and IND-related communications, and scientific presentations at Parkinson’s and neurodegeneration conferences. Company updates also cover the Magellan™ drug discovery platform, preclinical GCase modulator programs such as GT-04686, and pipeline areas including lysosomal storage disorders, metabolic diseases and solid tumors.
Gain Therapeutics, Inc. (Nasdaq: GANX) is set to present preclinical data at two significant medical meetings in September 2022. The first presentation will occur at the MDS 2022 International Congress in Madrid on September 17, featuring a poster on GT-02287, a promising allosteric regulator for Parkinson's disease. The second presentation will be at the GBA-PD Symposium in Jerusalem on September 22, discussing innovative strategies for GBA-PD. Gain's approach employs its unique computational discovery platform, SEE-Tx®, to drive advancements in drug development.
Gain Therapeutics (Nasdaq: GANX) announced that COO Matthias Alder will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York. The presentation is scheduled for September 12 at 7:00 AM ET and will be available via a webcast. Gain Therapeutics focuses on transforming drug discovery with its proprietary SEE-Tx® platform, targeting allosteric binding sites to develop treatments for various diseases, including neurodegenerative and metabolic disorders.
Gain Therapeutics, Inc. (Nasdaq: GANX) announced its participation in the 2022 BTIG Biotechnology Conference on August 9 at 12 p.m. ET. The event will take place in New York City on August 8-9. The company will engage in a fireside chat and host investor meetings. Gain's unique computational platform, SEE-Tx®, identifies novel allosteric binding sites to revolutionize drug discovery, targeting diseases like Parkinson’s. Their work has garnered funding from notable organizations, including The Michael J. Fox Foundation.
Gain Therapeutics, Inc. (Nasdaq: GANX) is set to present at the Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. COO Matthias Alder will host a corporate presentation on June 10 at 8:00 AM ET, with a live webcast available on the company's website. Gain Therapeutics focuses on transforming drug discovery through its proprietary technology, SEE-Tx®, which identifies novel allosteric binding sites for various diseases. Their pipeline targets neurodegenerative diseases, lysosomal storage disorders, and oncology, with significant funding support for their Parkinson’s disease program.
Gain Therapeutics, Inc. (Nasdaq: GANX) will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 1:30 PM ET. CEO Eric Richman is set to lead the corporate presentation and host one-on-one meetings during the event, which runs from May 23-25 in Miami, Florida. Gain is known for its innovative drug discovery platform that targets allosteric binding sites to create small molecule treatments for various diseases, including neurodegenerative disorders. A live webcast will be available on their website, and an archived version will follow.
Gain Therapeutics (GANX) reported a net loss of $3.27 million for Q1 2022, improving from a loss of $2.54 million in Q1 2021. Revenue increased to $45,000, driven by collaboration agreements. R&D expenses rose to $1.56 million, while general and administrative costs surged to $1.78 million. The company holds $34.34 million in cash, providing operational runway into the latter half of 2023. Notable preclinical data was presented for its lead candidate GT-02287 targeting Parkinson’s and Gaucher's diseases, suggesting its potential therapeutic benefits.
Gain Therapeutics (Nasdaq: GANX) showcased promising data for its lead compound GT-02329 targeting Gaucher disease at the 1st IWGDD Symposium. The compound boosts GCase levels and activity, effectively reducing toxic substrate accumulation in both human and mouse models. Specifically, the data highlighted increased GCase activity and decreases in glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). The company aims to further investigate GT-02329's potential as a therapy to alleviate neurological effects associated with Gaucher disease.
Gain Therapeutics, Inc. (Nasdaq: GANX) has announced promising pre-clinical results for its lead compound, GT-02287, targeting Parkinson’s Disease. Presented at the XXVII World Congress on Parkinson’s Disease, the compound successfully penetrates the brain, reduces alpha-synuclein levels, and improves dopamine production in neuronal models. Data showcases its ability to bind with the GCase protein, enhancing lysosomal function. The findings suggest potential disease-modifying effects, positioning GT-02287 as a candidate for clinical advancement this year.
Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will participate in a fireside chat at the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, from 2:00 to 2:30 p.m. ET. Investors are invited to join via webcast. Gain Therapeutics specializes in drug discovery using its proprietary computational platform, SEE-Tx®, targeting allosteric regulators for various diseases. The company’s lead program focuses on Parkinson’s disease, supported by funding from notable organizations.
Gain Therapeutics (Nasdaq: GANX) presented promising pre-clinical data for its lead candidate GT-02287 at the 2022 Synuclein Meeting in Belgium. The compound enhances GCase levels, promotes lysosomal health, and depletes alpha-synuclein, indicating potential benefits for Parkinson's Disease patients. Key findings include increased GCase activity and neuron survival in relevant models. CEO Eric Richman emphasized the candidate's disease-modifying potential, while the data supports a therapeutic strategy targeting GCase for neurodegenerative diseases.